Kenvue Q1 revenue rises 4.5%, beats estimates

Kenvue

07/05/2026 11:43

Overview

Consumer health products maker's fiscal Q1 revenue rose 4.5%, beating analyst expectations

Adjusted diluted EPS for fiscal Q1 rose 33% to $0.32

Company says margin gains driven by supply chain optimization and cost actions

Outlook

Kenvue will not provide forward-looking guidance due to pending merger with Kimberly-Clark

Result Drivers

SUPPLY CHAIN OPTIMIZATION - Co said margin improvements were largely due to productivity gains from global supply chain initiatives and favorable value realization

COST OPTIMIZATION - Cost actions, including the 2026 Restructuring Initiative and media cost improvements, reduced selling, general, and administrative expenses

SEGMENT PERFORMANCE - Organic sales growth in Skin Health and Beauty and Essential Health was offset by a decline in Self Care, which was impacted by weak cold and flu seasons

Company press release: ID:nBw7kdB0Za

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$3.91 bln
$3.84 bln (9 Analysts)
Q1 Adjusted EPS
$0.32
Q1 EPS
$0.25
Q1 Net Income
$474 mln
Q1 Gross Profit
$2.30 bln
Q1 Operating Income
$767 mln
Q1 Pretax Profit
$672 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 13 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the personal products peer group is "buy."

Wall Street's median 12-month price target for Kenvue Inc is $19.00, about 7.5% above its May 6 closing price of $17.68

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)